New brain scan tracer could spot Alzheimer's and Parkinson's earlier
NCT ID NCT07470710
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial will test a new radioactive tracer called 18F-FCOB04 in 40 people with neurodegenerative diseases like Alzheimer's or Parkinson's. The tracer targets a brain protein called MAO-B and is used with PET scans to see if it can help diagnose these conditions. The study focuses on safety and how the tracer behaves in the body.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
18F-FCOB04 (a radioactive tracer for PET imaging)
What this could lead to
If successful, this could lead to a new imaging tool to help doctors diagnose neurodegenerative diseases more accurately and earlier.
What could go wrong
This is a very early, small study (40 people) focused on safety and imaging patterns, not treatment. It may not lead to a widely used diagnostic test.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.